Lv11
50 积分 2025-07-28 加入
KRAS mutation-driven O-GlcNAcylation of CLDN18.2 enhances the progression of pancreatic cancer and reduces the efficacy of CLDN18.2-targeted therapy
13天前
已完结
Combinatorial strategies to target RAS-driven cancers
13天前
已完结
Intermediate-risk Non–muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group
9个月前
已完结
miR-19a-mediated downregulation of RhoB inhibits the dephosphorylation of AKT1 and induces osteosarcoma cell metastasis
10个月前
已完结
皖公网安备34019202002308
